Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over

BACKGROUND: Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old have not been included in previous clinical trials. AIM: To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for e...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:World J Hepatol
Main Authors: Tamai, Hideyuki, Shingaki, Naoki, Ida, Yoshiyuki, Shimizu, Ryo, Maeshima, Shuya, Okamura, Junpei, Kawashima, Akira, Nakao, Taisei, Hara, Takeshi, Matsutani, Hiroyoshi, Nishikawa, Izumi, Higashi, Katsuhiko
Format: Artigo
Sprog:Inglês
Udgivet: Baishideng Publishing Group Inc 2020
Fag:
Prospective Study
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7522558/
https://ncbi.nlm.nih.gov/pubmed/33033572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v12.i9.672
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker